Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP),...

Lung cancer is the leading cause of cancerrelated mortality worldwide and annually responsible for more than 500,000 deaths worldwide. Approximately 80% of the lung cancer patients have non-small cell lung cancer (NSCLC). Once diagnosed, survival rates are low. Even diagnosed early, grade I lung cancer patients have only a 6070% five-year survival rate. Although interventions have been improved...

RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP),...

Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis ...

Lung cancer is in Poland the most common malignancy. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung tumors. In the multidisciplinary treatment of non-small cell lung cancer patients the role of chemotherapy and, most recently, molecular targeted therapy is increasing. In 2005 we published recommendations for systemic treatment of non-small cell lung cancer and mes...

The use of next-generation tyrosine kinase inhibitors has led to improved progression-free survival for patients with metastatic non–small cell lung cancer (NSCLC) and those EGFR -mutant ALK -positive tumors. Newer therapeutics can now target KRAS G12C mutations, exon 20 insertions, ERBB2 ( HER2) mutations. Patients NSCLC should undergo molecular testing these mutations as well BRAF mutations; ...

The present study aimed to investigate the expression profile of AXL in non-small cell lung cancer (NSCLC) and its clinical significance. The current study included 257 NSCLC patients, tyrosine-protein kinase receptor UFO (AXL) expression in paired lung cancer and adjacent normal lung tissues of NSCLC patients were compared by immunohistochemistry, western blot analysis and quantitative polymer...

This clinical lecture demonstrates the current and future role of 18-F FDG PET/CT in diagnosis NSCLC (non-small cell lung cancer) (usefulness/limitations) prognosis cancer treatment. PET-CT combines metabolic morphological data, which makes it possible to offer better possibilities for diagnosing malignant pulmonary nodules compared conventional CT. Integrated advantages PET CT, minimizing thei...

The acceptable treatment strategy currently in the of locally advanced non-small cell lung cancer (LA-NSCLC) patients is combination treatment, but concurrent chemoradiotherapy (CCRT) has been associated with significant toxicities. aim this study was to assess ability Endostar and amifostine (AM) reduce incidence chemoradiotherapy-induced pneumonitis above grade 2 stage III NSCLC. Patients NSC...